1. What Else Can CD39 Tell Us?
   Hai Zhao et al, 2017, Front. Immunol. CrossRef
2. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives
   Paola de Andrade Mello et al, 2017, Front. Immunol. CrossRef
3. Extracellular ATP signaling and clinical relevance
   Lei Dou et al, 2017, Clinical Immunology CrossRef
4. Ectonucleotidase CD39 expression in regional metastases in head and neck cancer
   Magis Mandapathil et al, 2018, Acta Oto-Laryngologica CrossRef
5. Targeting adenosine for cancer immunotherapy
   Robert D. Leone et al, 2018, j. immunotherapy cancer CrossRef
6. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
   Linsen Shi et al, 2018, International Immunopharmacology CrossRef
7. Prognostic impacts of adenosine-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy
   Ryuma Tokunaga et al, 2018, Clinical Colorectal Cancer CrossRef
8. Altered cancer metabolism in mechanisms of immunotherapy resistance
   Rishab Ramapriyan et al, 2018, Pharmacology & Therapeutics CrossRef
9. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
   Simone de Leve et al, 2019, Front. Immunol. CrossRef
10. Progress in the treatment of advanced gastric cancer.
    Zheyu Song et al, 2017, Tumour Biol CrossRef
11. Targeting the adenosine pathway for cancer immunotherapy
    Akil Hammami et al, 2019, Seminars in Immunology CrossRef
12. Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non–small-cell Lung Cancer
    Anders Tøndell et al, 2020, Translational Oncology CrossRef
13. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line
    Julia Biz Willig et al, 2020, Purinergic Signalling CrossRef
14. The TGF‐b/SOX4 axis and ROS‐driven autophagy co‐mediate CD39 expression in regulatory T‐cells
    Marlene C. Gerner et al, 2020, FASEB j. CrossRef
15. Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective
    Huang-Yu Yang et al, 2020, IJMS CrossRef
16. Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance
    Fang Wei et al, 2020, Cell. Mol. Life Sci. CrossRef
17. Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
    Shin Foong Ngiow et al, 2020, Front. Immunol. CrossRef
18. Implications of CD39 in immune-related diseases
    Jianrui Zeng et al, 2020, International Immunopharmacology CrossRef
19. Targeting adenosine and regulatory T cells in cancer immunotherapy
    Alexey Churov et al, 2021, Human Immunology CrossRef
20. If Small Molecules Immunotherapy Comes, Can the Prime be Far Behind?
    Jingyu Zhang et al, 2021, European Journal of Medicinal Chemistry CrossRef
21. Treatment Strategies of Gastric Cancer—Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review
    Magdalena Tyczyńska et al, 2021, J Gastrointest Canc CrossRef
22. Integrated bioinformatics analysis and screening of hub genes in papillary thyroid carcinoma
    Rong Fan et al, 2021, PLoS ONE CrossRef
23. Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
    F. Brauneck et al, 2021, OncoImmunology CrossRef
24. Surface AMP deaminase 2 as a novel regulator modifying extracellular adenine nucleotide metabolism
    Lisa Ehlers et al, 2021, FASEB j. CrossRef
25. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints
    Elham Baghbani et al, 2021, Life Sciences CrossRef
26. Arginase pathway markers of immune-microenvironment in thymic epithelial tumors and small cell lung cancer
    Shigeki Umemura et al, 2021, Clinical Lung Cancer CrossRef
27. Clinical significance and prognostic role of an immune-related gene signature in gastric adenocarcinoma
    Rui Mao et al, 2021, Aging CrossRef
28. CD39 Regulation and Functions in T Cells
    Eleonora Timperi et al, 2021, IJMS CrossRef
29. Favorable function of Ectonucleoside triphosphate diphosphohydrolase 1 high expression in thyroid carcinoma
    Jun-hua Luo et al, 2021, Hereditas CrossRef
30. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors
    H O Ramdani et al, 2021, Pathology - Research and Practice CrossRef
31. CD142 plays a key role in the carcinogenesis of gastric adenocarcinoma by inhibiting BCL2-dependent autophagy
    Weifeng Xu et al, 2021, Biochem. Cell Biol. CrossRef
32. Genetically driven CD39 expression affects Sezary cell viability, IL-2 production and detects two patient subsets with distinct prognosis
    Mario Picozza et al, 2022, Journal of Investigative Dermatology CrossRef
33. Adenosine signaling: Optimal target for gastric cancer immunotherapy
    Junqing Wang et al, 2022, Front. Immunol. CrossRef
34. Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review
    Sarbajit Mukherjee et al, 2022, Ther Adv Med Oncol CrossRef
35. Overexpression of Potential Markers of Regulatory and Exhausted CD8+ T Cells in the Peripheral Blood Mononuclear Cells of Patients with B-Acute Lymphoblastic Leukemia
    Mahdieh Naghavi Alhosseini et al, 2023, IJMS CrossRef
36. Nucleotide metabolism: a pan-cancer metabolic dependency
    Nicholas J. Mullen et al, 2023, Nat Rev Cancer CrossRef
37. null
    Rebecca Borella et al, 2023 CrossRef